CNBC Article Rating

Bernstein says Elon Musk's pro GLP-1 stance may boost Eli Lilly, sees nearly 40% upside

  • Bias Rating

    -2% Center

  • Reliability

    30% ReliableFair

  • Policy Leaning

    10% Center

  • Politician Portrayal

    -24% Negative

Bias Score Analysis

The A.I. bias rating includes policy and politician portrayal leanings based on the author’s tone found in the article using machine learning. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral.

Sentiments

Overall Sentiment

3% Positive

  •   Liberal
  •   Conservative
SentenceSentimentBias
Unlock this feature by upgrading to the Pro plan.

Bias Meter

Extremely
Liberal

Very
Liberal

Moderately
Liberal

Somewhat Liberal

Center

Somewhat Conservative

Moderately
Conservative

Very
Conservative

Extremely
Conservative

-100%
Liberal

100%
Conservative

Bias Meter

Contributing sentiments towards policy:

65% : The first was a recent report of Eli Lilly CEO David Ricks' attendance at a dinner with Trump and Kennedy, along with leaders from Pfizer and the Pharmaceutical Research and Manufacturers of America.
24% : Eli Lilly shares also tumbled after Trump announced Robert F. Kennedy Jr., a noted skeptic of vaccines and well-known weight loss drug Ozempic , as his pick to lead Health and Human Services secretary.

*Our bias meter rating uses data science including sentiment analysis, machine learning and our proprietary algorithm for determining biases in news articles. Bias scores are on a scale of -100% to 100% with higher negative scores being more liberal and higher positive scores being more conservative, and 0% being neutral. The rating is an independent analysis and is not affiliated nor sponsored by the news source or any other organization.

Copy link